Progenics Pharmaceuticals Inc. (PGNX)’s Financial Results Comparing With Tenax Therapeutics Inc. (NASDAQ:TENX)

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and Tenax Therapeutics Inc. (NASDAQ:TENX) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Progenics Pharmaceuticals Inc. 16.71M 20.74 72.97M -0.87 0.00
Tenax Therapeutics Inc. N/A 0.00 14.57M -8.14 0.00

Table 1 demonstrates Progenics Pharmaceuticals Inc. and Tenax Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Progenics Pharmaceuticals Inc. -436.68% -65.5% -35%
Tenax Therapeutics Inc. 0.00% -182.8% -165.8%

Risk and Volatility

Progenics Pharmaceuticals Inc.’s volatility measures that it’s 139.00% more volatile than S&P 500 due to its 2.39 beta. Tenax Therapeutics Inc.’s 30.00% more volatile than S&P 500 volatility due to the company’s 1.3 beta.

Liquidity

Progenics Pharmaceuticals Inc.’s Current Ratio is 6.1 while its Quick Ratio is 6.1. On the competitive side is, Tenax Therapeutics Inc. which has a 8.5 Current Ratio and a 8.5 Quick Ratio. Tenax Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Progenics Pharmaceuticals Inc.

Analyst Ratings

Progenics Pharmaceuticals Inc. and Tenax Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Progenics Pharmaceuticals Inc. 0 0 2 3.00
Tenax Therapeutics Inc. 0 0 0 0.00

The upside potential is 168.95% for Progenics Pharmaceuticals Inc. with average target price of $11.

Institutional and Insider Ownership

Institutional investors owned 85.7% of Progenics Pharmaceuticals Inc. shares and 14.3% of Tenax Therapeutics Inc. shares. 6.46% are Progenics Pharmaceuticals Inc.’s share owned by insiders. Comparatively, Tenax Therapeutics Inc. has 4.73% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Progenics Pharmaceuticals Inc. -6.51% -4.87% 6.09% -9.8% -34.41% 16.19%
Tenax Therapeutics Inc. -11.26% -17.06% 19.32% -66.19% -77.21% 17.35%

For the past year Progenics Pharmaceuticals Inc. has weaker performance than Tenax Therapeutics Inc.

Summary

On 6 of the 10 factors Progenics Pharmaceuticals Inc. beats Tenax Therapeutics Inc.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.